These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 19567518

  • 1. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.
    Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, Nightingale P, Tomlinson JW, Arlt W, Stewart PM.
    J Clin Endocrinol Metab; 2009 Sep; 94(9):3558-66. PubMed ID: 19567518
    [Abstract] [Full Text] [Related]

  • 2. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
    Tsilchorozidou T, Honour JW, Conway GS.
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
    [Abstract] [Full Text] [Related]

  • 3. Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome.
    Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W.
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2760-6. PubMed ID: 12788885
    [Abstract] [Full Text] [Related]

  • 4. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
    Moran C, Arriaga M, Arechavaleta-Velasco F, Moran S.
    J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
    Markopoulos MC, Rizos D, Valsamakis G, Deligeoroglou E, Grigoriou O, Chrousos GP, Creatsas G, Mastorakos G.
    J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome.
    Gambineri A, Forlani G, Munarini A, Tomassoni F, Cognigni GE, Ciampaglia W, Pagotto U, Walker BR, Pasquali R.
    J Endocrinol Invest; 2009 Mar; 32(3):210-8. PubMed ID: 19542736
    [Abstract] [Full Text] [Related]

  • 9. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
    Alpañés M, Luque-Ramírez M, Martínez-García MÁ, Fernández-Durán E, Álvarez-Blasco F, Escobar-Morreale HF.
    Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
    [Abstract] [Full Text] [Related]

  • 10. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
    Gambineri A, Vicennati V, Genghini S, Tomassoni F, Pagotto U, Pasquali R, Walker BR.
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2295-302. PubMed ID: 16551740
    [Abstract] [Full Text] [Related]

  • 11. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome.
    Chen MJ, Han DS, Yang JH, Yang YS, Ho HN, Yang WS.
    Hum Reprod; 2012 Aug; 27(8):2476-83. PubMed ID: 22693174
    [Abstract] [Full Text] [Related]

  • 12. 5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche.
    Silfen ME, Shackleton CH, Manibo AM, Levine LS, Sekhar D, McMahon DJ, Oberfield SE.
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4647-51. PubMed ID: 12364451
    [Abstract] [Full Text] [Related]

  • 13. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
    Tziomalos K, Katsikis I, Papadakis E, Kandaraki EA, Macut D, Panidis D.
    Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
    [Abstract] [Full Text] [Related]

  • 14. Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls.
    Gambineri A, Fanelli F, Tomassoni F, Munarini A, Pagotto U, Andrew R, Walker BR, Pasquali R.
    Eur J Endocrinol; 2014 Jul; 171(1):47-57. PubMed ID: 24743397
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome.
    Münzker J, Hofer D, Trummer C, Ulbing M, Harger A, Pieber T, Owen L, Keevil B, Brabant G, Lerchbaum E, Obermayer-Pietsch B.
    J Clin Endocrinol Metab; 2015 Feb; 100(2):653-60. PubMed ID: 25387259
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.